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Nasogastric Aspiration as an Indicator for Feed Absorption in Model-Based Glycemic Control in Neonatal Intensive Care Introduction
St ress-induced hyperglycemia is a common complication for preterm infants in the neonatal intensive care unit (NICU) due to underdeveloped glycemic regulation mechanisms in the neonatal body and hormone-based stress response. 1 Prevalence of hyperglycemia is linked to increased mortality, 2 risk of complications such as intraventricular hemorrhage, 3 ventilator dependence, 4 and length of stay. 3, 4 There is neither a widely accepted method or approach for glycemic control in this cohort nor specified best blood glucose (BG) targets. 5 Glycemic control protocols often use fixed methods that do not account for interpatient and intrapatient variability 6 or are ad hoc and rely extensively on clinical experience. 7 Some protocols rely on varied nutritional inputs that may adversely affect growth. 8 Using insulin to treat hyperglycemia has been linked to positive outcomes [8] [9] [10] [11] [12] but has proven difficult and risky. 9 Model-based glycemic control has shown positive outcomes in both the NICU and the adult intensive care unit. 13, 14 These methods capture interpatient variability and evolving patient condition to best describe a patient's sensitivity to insulin 14, 15 in contrast to fixed protocols that typically assume a constant insulin sensitivity across all patients and weight-based methods, both of which neglect changes in a patient's metabolic condition. Both of these frameworks are inaccurate, resulting in poor control and hypoglycemia. 7, 15 The STAR (stochastic targeted) framework uses model-based control methods to identify patient-specific insulin sensitivity and forecast how this will change between clinical interventions using a stochastic model. 13, 15 Using this forecasted insulin sensitivity and the clinically validated NICING model, 15 an optimal treatment is selected that overlaps a forecast BG range with a clinically defined target band. It thus ensures a specific risk of hypoglycemic or hyperglycemic outcomes for each intervention.
Knowledge of nutritional inputs is critical for accurate metabolic modeling and control. As it is impractical to measure feed absorption directly, models typically make the assumption that given feed is absorbed by some regular transfer mechanism. However, actual feed absorption is uncertain and may vary over time and between patients. This adds uncertainty to the forecast changes in patient glycemia and condition, potentially leading to poorer control. This research investigates the use of nasogastric aspirates to indicate poor feed absorption and its potential to improve glycemic control.
Methods

Aspirates
Nasogastric aspiration is the process of feeding a nasogastric tube into the stomach of a patient and draining the stomach contents by suction. This action is normally performed for neonates as they are introduced to enteral feed, typically expressed breast milk, to ensure digestion is functioning correctly and to remove bile or gastric secretions. Occasionally, the contents of these aspirates are large in volume and milky in texture, indicating that a significant fraction of given feed remains in the stomach and thus has not been absorbed. Such variations may significantly alter modeled response.
NICING Model
The clinically validated NICING model, 15 with the variables and parameters given in Table 1 , is defined as follows: Aspirate data were analyzed retrospectively. Aspirates of interest met the following criteria:
• The patient was receiving insulin,
• The patient was currently on an enteral feed of 1 ml/h or more, and
• One of either o The size of the aspirate taken was at least half the volume of the feed given in the last 4 h or o The aspirate exceeded 2 ml in volume.
Data collected included time, aspirate volume, a qualitative description of the consistency (milky, bile), and whether the contents were returned to the stomach. The enteral feeds given for the last 4 h were already recorded by STAR.
Aspirate consistency recorded by clinicians was a qualitative measure, primarily used to indicate unusual aspirates. As such, this measure was likely subjective and not particularly useful for analysis. Instead, aspirate consistency is discriminated in analysis between aspirates that were returned and those that were not returned.
From a cohort of 35 patients, 8 had aspirates that fit these criteria, with a total of 108 aspirates of interest over 959 h of data. The median gestational age of the included group was 25 weeks, and median postnatal age was 5.5 days. All patients were younger than 28 weeks. These 8 patients are summarized in Table 2 . No patients in the cohort were on trophic feeds. However, enteral feed volumes were not necessarily great enough to be considered full nutrition. The volumes of medications were small compared with enteral feed rates and so have been neglected. A summary of the cohort's additional medicinal requirements is given in Table 3 .
Modeling Poor Feed Absorption
Aspirates are accounted for using a simple feed redistribution model. When significant aspirates are taken, they are removed from the patient's enteral feed profile over recent hours; if they are returned, they are added to the feed profile at the time that they are returned. A simple diagram of this process is shown in Figure 1 .
Aspirates that have been recorded are assumed to be equivalent in volume to enteral feed that has failed to absorb. The balance of the aspirate is taken from enteral boluses from the patient's feed profile, starting from the most recent feed. Thus a 2.5 ml aspirate given a feed rate of 1 ml every hour for the prior 4 h is removed as 1 ml from each of the immediately prior 2 h and 0.5 ml from the third prior hour. This process was performed for both milky and bile-like aspirates.
When an aspirate is returned, it is assumed to be equivalent to giving the patient an enteral feed bolus of that volume. The concentration of the returned aspirate is modeled as equal to the concentration of the most recent enteral feed.
Virtual patients 15, 16 were created using the NICING model of Equations (1)- (7) and clinical data. A virtual patient is defined by a time-varying, patient-specific insulin sensitivity (S I ) found by fitting Equations (1)- (7) to clinical data. Two cases are compared: (1) the model fit to clinical data, when aspirates are not accounted for, and (2) the model fit when aspirates are modeled via the modified enteral feed profile described. Thus there are two sets of virtual patients created, where one accounts for changes in enteral absorption and the other does not.
Analysis and Impact on Control
Insulin sensitivity (S I ) describes insulin-mediated removal and changes in patient metabolic state, in particular, capturing changes in endogenous glucose and insulin secretion and peripheral insulin sensitivity. In the case of poorly absorbed feeds, there is reduced appearance of glucose in the blood plasma. If this reduction is not accounted for in the model, it is seen as an increase in insulin sensitivity. It is hypothesized that, by explicitly modeling poor feed absorption, variation in S I will be reduced, thus improving the tightness of glycemic control.
Changes in S I between these cases are measured both as absolute values and as fractional changes, with respect to the volume of the aspirate. They are examined for 4 h either side of an aspirate event.
The impact of modeling feed uptake using aspirates on tight glycemic control is evaluated in silico using clinically validated virtual trials. 16 The STAR framework 15, 17 uses insulin sensitivity and the NICING model to describe the current metabolic state of a neonate. Stochastic forecasting is used to quantify variation in S I over the coming intervention interval, allowing treatments to be selected that find corresponding BG levels that overlap with a clinical target band.
In virtual trial simulation, four cases were investigated, as shown in Table 4 , by selecting which S I profiles are seen in the simulation of the patient response and the control protocol. The S I profile selected for simulation describes the response of the virtual patient based on clinical data. In contrast, the S I profile selected for control describes the current patient condition from which stochastic forecasting and treatment selection is based. The four cases compare the impact of assuming aspirates are (or are not) important in control for cases where aspirates and changes in enteral feed profile have (aspirates virtual cohort) or have not (original cohort) a physiological impact. Three-hour windows are used in this case, as this is the typical length of the insulin intervention interval.
Four performance metrics are used to assess virtual trials. For performance, a maximal fraction of BG measurements within 72-144 mg/dl (time in band) and a minimal fraction of measurements that are in excess of 180 mg/dl (hyperglycemia) is desirable. For safety, minimizing the fraction of BG measurements <54 mg/dl (hypoglycemia) and the number below 47 mg/dl (severe hypoglycemia) is desired. Finally, interventions are compared between the four cases to indicate how accounting for aspirates modified insulin treatment interventions. 
Results
Figure 2
shows that S I is lower in the hours before an aspirate is taken when it has been accounted for, as expected. Similarly, S I is greater following an aspirate when the contents have been returned to the stomach, because insulinmediated glucose removal appears higher. Aspirate events appear to generate first-order impulse responses in the change ΔS I , where the magnitude of the change in S I decays for times farther away from the event. Although the enteral feed profile has been manipulated for a maximum of 4 h before the event, changes to S I appear to last longer. Where aspirates are not returned, as shown for patient 2 in Figure 2 , changes to S I are always negative. These results match hypothesized expectations.
The absolute difference in S I between both methods is analyzed over the 4 h either side of each aspirate. Changes are also given where they are weighted by the volume of the aspirate. The median magnitude of the change in S I is shown in Table 5 as an absolute value, weighted by aspirate size, and as a percentage. The fractional change in S I as a function of the aspirate volume is shown in Figure 3 for all events 4 h before and after the time of the aspirate. There is no distinct relationship between the fractional change in S I and the aspirate volume.
The effect of aspirates on glycemic control is shown in Table 6 . Changes in the percentage of time in band across the eight patients are minimal. Contrasting patients where aspirates were or were not included in simulation shows a difference of less than 0.3% of BG measurements in the target band 72-144 mg/dl.
The change in insulin interventions in Table 6 between accounting and not accounting for aspirates is also small. For the virtual cohort with an original feed profile, accounting for aspirates reduces insulin inputs in the 3 h following an aspirate by a median and interquartile range of 0.0044 (0.0017-0.0064) U/kg/h. By contrast, the Control results for two patients with no returned feeds are shown separately in Table 7 . These patients are independent of the assumption that returned aspirates can be modeled as an enteral bolus at the time that it is returned. These patients make up 300 h of data, 102 BG measurements, and 12 of the total 108 aspirates. As with the results shown in Table 6 , results for these patients are very similar between tested protocols, indicating that modeling returned feeds as an enteral bolus also does not significantly alter results. 
Discussion
Simulating virtual trials with aspirates had a negligible impact on control performance, as did attempting to control for them. The lack of a distinct relationship between aspirate volume and changes in S I suggests that other aspects of patient condition or control have a more significant effect on fitting S I than enteral feed. The change in control inputs due to aspirates was also minimal, less than twice the minimum resolution of the insulin pump used.
Only 8 long-term patients from a cohort of 35 (22%) from Le Compte and coauthors 14 had significant aspirates. Of these patients, 3 had less than one notable aspirate per day on average, and only 3 patients had more than three mean aspirates per day.
Accounting for aspirates had a small overall effect on the glycemic modeling and control process. This is reflected in changes to identified S I , insulin recommendations by STAR, and control outcomes in virtual trials. Changes in S I due to accounting for aspirates were less than 2% in magnitude. This suggests that the NICING model is generally robust against the uncertainty introduced by neglecting to account for significant aspirates.
In virtual trials, insulin doses recommended by STAR do not notably deviate when aspirates are accounted for. Hence, if aspirate details were recorded into STAR and factored into the selection of a treatment in a clinical setting, the insulin recommendation would not be notably different. This fact challenges whether the inclusion of such an element would be relevant. The increased nurse workload from entering this additional information would increase clinical burden and potential for error. 18, 19 Furthermore, if nurses are aware of the minimal impact of recording aspirates, they may knowingly omit this data to reduce workload, reducing protocol compliance.
Finally, control outcomes in virtual trials show a negligible change in the number of BG measurements inside identified target bands. It is undesirable to include additional complexity to the model without a noted improvement in the quality of control given.
